Connect Biopharma Holdings Limited (CNTB)
CNTB Stock Price Chart
Explore Connect Biopharma Holdings Limited interactive price chart. Choose custom timeframes to analyze CNTB price movements and trends.
CNTB Company Profile
Discover essential business fundamentals and corporate details for Connect Biopharma Holdings Limited (CNTB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Mar 2021
Employees
62.00
Website
https://www.connectbiopharm.comCEO
Barry D. Quart
Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
CNTB Financial Timeline
Browse a chronological timeline of Connect Biopharma Holdings Limited corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 13 Aug 2025
EPS came in at -$0.23 falling short of the estimated -$0.22 by -4.55%, while revenue for the quarter reached $6.70K .
Earnings released on 15 May 2025
EPS came in at -$0.19 surpassing the estimated -$0.27 by +29.63%, while revenue for the quarter reached $261.88K .
Earnings released on 5 Sept 2024
EPS came in at $0.02 surpassing the estimated -$0.03 by +167.49%, while revenue for the quarter reached $3.32M , beating expectations by +12.54%.
Earnings released on 16 Apr 2024
EPS came in at -$0.07 falling short of the estimated -$0.03 by -131.68%.
Earnings released on 12 Sept 2023
EPS came in at -$0.08 surpassing the estimated -$6.92 by +98.89%.
Earnings released on 11 Apr 2023
EPS came in at -$0.15 surpassing the estimated -$3.58 by +95.80%.
Earnings released on 13 Sept 2022
EPS came in at -$0.16 surpassing the estimated -$5.28 by +96.93%.
Earnings released on 31 Mar 2022
EPS came in at -$0.17 surpassing the estimated -$4.38 by +96.22%.
Earnings released on 31 Aug 2021
EPS came in at -$0.48 surpassing the estimated -$2.36 by +79.66%.
Earnings released on 19 Mar 2021
EPS came in at -$0.00 .
CNTB Stock Performance
Access detailed CNTB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.